Israel to launch world's first human spinal cord transplant using patient's own cells
Tired of too many ads?
Remove Ads
A Revolutionary Surgical Approach
Impact on Patients' Lives
Israel's Role in Medical Innovation
Tired of too many ads?
Remove Ads
FAQs:
In a groundbreaking development in regenerative medicine Israeli scientists are getting ready to perform the world's first spinal cord transplant using a patient's own cells. Announced on August 20, 2025, by Tel Aviv University , this pioneering procedure could redefine the treatment options for spinal cord injury diagnosis and give new hope for patients who have long faced restricted options.The surgery will involve transplanting a patient's own cells into the damaged areas of the spinal cord. The aim is to restore lost functions, allowing patients to regain mobility. Unlike traditional treatments that rely on donor tissues or artificial implants, this process leverages the patient's biological material, minimizing the risk of rejection and enhancing the chances of successful integration.Experts regard that this approach represents a major leap forward in spinal cord therapy. By leveraging the patient's own cells, doctors focus to stimulate neural regeneration and repair, allowing individuals to walk again after severe injuries. If successful, the process could set a global precedent for how spinal cord injuries are diagnosed in the future.Spinal cord injuries usually result in permanent loss of sensation and movement, then affecting quality of life. The innovative transplant will mitigate these effects by repairing neural pathways and initiating recovery. For patients and families who have faced the long-term issues of immobility, this breakthrough could bring renewed hope for rehabilitation and renewed independence.Israel has long been at the forefront of medical research, with advancements spanning oncology, cardiology, and neurology. The upcoming spinal cord transplant highlights the country's commitment to pioneering answers that push the boundaries of conventional medicine. Collaboration between Tel Aviv University and leading medical institutions demonstrates how academic research can be translated into clinical practice, benefiting patients worldwide.A1. A spinal cord transplant is a medical process that focuses to repair damaged spinal tissue, restore lost neural functions, and potentially enable patients to regain mobility.A2. Regenerative medicine uses the body's own cells or biological materials to repair, replace, or regenerate damaged tissues and organs, initiating natural healing and recovery.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
First Post
8 hours ago
- First Post
Spain: Motor Yacht 'Da Vinci' Catches Fire, Sinks off Formentera
Spain: Motor Yacht 'Da Vinci' Catches Fire, Sinks off Formentera | Vantage with Palki Sharma A 29-metre motor yacht, 'Da Vinci' caught fire off the coast of Formentera in Spain on Monday. While authorities managed to rescue all seven aboard -- including four passengers, two crew and the captain -- the yacht sunk due to fire damage. Also on Vantage Shots: - Israeli military claims it blew up Hamas tunnels in Gaza. - Parisians cool off in the Seine as a heatwave sweeps over France. - On this day in 1990, a nearly-complete skeleton of a tyrannosaurus rex was discovered. The specimen was 65 million years old. The bones were extremely well-preserved, with 90% of them intact. The discovery allowed scientists to learn everything they know about the dinosaur. See More
Time of India
10 hours ago
- Time of India
World's first human spinal cord implant to take place in Israel
Tel Aviv: Israel is preparing to perform the world's first-ever human spinal cord implant using a patient's own cells, a medical breakthrough that could allow paralysed patients to stand and walk again, Tel Aviv University announced on Wednesday. The surgery, expected in the coming months, will take place in Israel and marks a historic milestone in regenerative medicine . According to the World Health Organisation, over 15 million people worldwide are living with spinal cord injuries , with the majority resulting from traumatic causes such as falls, road traffic accidents, and violence. Currently, spinal cord injuries cannot be fully cured, so treatment focuses on stabilising the patient, preventing further damage, and maximising function. Emergency care often involves immobilising the spine, reducing inflammation, and sometimes performing surgery to repair fractures or relieve pressure. Rehabilitation includes physical and occupational therapy, as well as assistive devices like wheelchairs and braces. While experimental therapies--including stem cells and robotic devices--are being explored, no treatment yet reliably restores full spinal cord function. Spinal cord injuries are one of the few human injuries where the body cannot naturally heal itself, and the tissue is both structurally complex and extremely sensitive. "The spinal cord transmits electrical signals from the brain to all parts of the body. When it is severed by trauma such as a car accident, a fall, or a combat injury, the chain is broken. Think of an electrical cable that has been cut: when the two ends no longer touch, the signal cannot pass, and the patient remains paralysed below the injury," explained Professor Tal Dvir, head of the Sagol Centre for Regenerative Biotechnology and the Nanotechnology Centre at Tel Aviv University, who is leading the effort. Dvir is also the chief scientist at Matricelf , the Israeli biotech company commercialising the technology. Unlike other tissues, spinal cord neurons cannot naturally regenerate, and over time, scar tissue blocks remaining signals. The new procedure aims to replace the damaged section with a lab-grown spinal cord that fuses with healthy tissue above and below the injury. Animal studies in rats have shown remarkable results, with the animals regaining the ability to walk normally. The innovation began about three years ago, when Dvir's lab engineered a personalised three-dimensional human spinal cord in the laboratory. The findings, published in the peer-reviewed journal Advanced Science, showed that mice with chronic paralysis regained mobility after receiving the engineered implants. The procedure begins with blood cells from the patient, which are reprogrammed into stem-cell-like cells capable of becoming any cell type. Fat tissue is also collected to create a custom hydrogel scaffold, into which the stem-like cells develop into a spinal cord structure. This engineered tissue is then implanted, replacing scarred areas and reconnecting the nervous system. A few months ago, Prof. Dvir and his team received preliminary approval from Israel's Ministry of Health for "compassionate use" trials in eight patients, making Israel the first country to attempt this procedure. "This is undoubtedly a matter of national pride. The technology was developed here in Israel, at Tel Aviv University and at Matricelf, and from the very beginning it was clear to us that the first-ever surgery would be performed in Israel, with an Israeli patient," Dvir said. The technology was then commercialised through Matricelf, which was founded in 2019 under a licensing agreement with Tel Aviv University's technology transfer company, Ramot. "This milestone marks the shift from pioneering research to patient treatment. Using each patient's own cells eliminates key safety risks and positions Matricelf at the forefront of regenerative medicine. This first procedure is more than a scientific breakthrough; it is a step toward transforming an area of medicine long considered untreatable," said Matricelf CEO Gil Hakim. He added, "If successful, this therapy could define a new standard of care in spinal cord repair, addressing a multi-billion-dollar market with no effective solutions today. We are proud that Israel is leading this global effort and are fully committed to bringing this innovation to patients worldwide." "Our goal is to help paralysed patients rise from their wheelchairs. The animal model trials showed extraordinary success, and we are hopeful that the results in humans will be just as promising," Dvir said.
Time of India
10 hours ago
- Time of India
Human fetal kidney development mimicked in test tubes
Researchers are a step closer to learning how congenital kidney defects develop in the fetus and how they might be prevented, a new report shows. For the first time, they can watch miniature human fetal kidneys develop in test tubes over periods that simulate the course of a pregnancy. So-called kidney organoids have been grown in test tubes before, but only starting with pluripotent stem cells - immature cells found in early embryos that can differentiate into any cell type in the body but without the tissue-specific characteristics that would allow them to perform an organ's specialized functions. In contrast, the new organoids are grown in test tubes using the same fetal progenitor stem cells that are destined to develop into human kidneys. These cells are capable of building, maintaining and repairing specific organs - in this case, the kidneys. While kidney organoids grown from pluripotent stem cells have survived in test tubes for weeks, the new organoids built from the human fetal kidney stem cells can survive and grow for six to eight months, essentially allowing researchers to observe human kidney development as it would happen during a pregnancy, the research team reported in The EMBO Journal. "Once we had the tissue stem cells coming from the developing human kidney in the Petri dish, they did the job because this is what they do in nature," said Dr. Benjamin Dekel of Safra Children's Hospital at Sheba Medical Center and Tel Aviv University, who led the research. "The cells are self-assembling. They know how to self-organize and how to self-renew, (that is) make copies of themselves," Dekel said. At the same time, Dekel continued, the cells begin to differentiate, developing qualities that make them appropriate for different roles. Researchers can watch as kidney tubules, ducts, blood vessels and other renal tissues are formed. In his clinical practice, Dekel treats children with kidney diseases. He hopes eventually to use the organoids to study kidney malformations and to isolate genes that lead to birth defects, develop new treatments in the field of regenerative medicine and test the toxicity of drugs during pregnancy on fetal kidneys. In the meantime, he said, it's frustrating to watch as patients' chronic kidney disease worsen into end-stage renal disease. "Then we need to give them a kidney transplant or to put them on dialysis, which is really a very poor solution," he said. MOVING CLOSER TO EFFECTIVE VACCINES FOR HPV-RELATED CANCERS New findings help explain why experimental treatments for cancers caused by human papillomavirus infections have been less than effective, researchers say. The most common cancer-causing strain of HPV undermines the body's defenses by reprogramming immune cells surrounding the tumor, earlier research has shown. Blocking this process can boost the ability of experimental treatments for HPV to eliminate cancer cells, according to a report published in the Journal for ImmunoTherapy of Cancer. While vaccines exist to prevent HPV infections, researchers have failed to develop effective " therapeutic vaccines " for use after HPV infections have occurred - and the new study helps explain why. Experimental therapeutic vaccines target HPV-infected cells with immune cells known as T-cells. But in tests in mice and cell cultures, researchers found that two HPV proteins, E6 and E7, prompt nearby cells to release a protein called IL-23 that prevents the body's T-cells from attacking the tumor. "In order to eliminate the cancer, T-cells need to proliferate and destroy infected cells. But IL-23 stops them from working effectively, so the tumor keeps growing," study leader W. Martin Kast of the Keck School of Medicine of the University of Southern California said in a statement. Drugs that inhibit IL-23 are already approved for treating psoriasis and other conditions, the researchers said. "The fact that these antibodies are already FDA-approved for something else makes this approach promising - and it also allows for rapid translation into the clinic," Kast said. He and his team are now developing their own therapeutic vaccine, which they will test in combination with antibodies that block IL-23. IL-23 is also found at high levels in testicular and bladder cancers, the researchers noted, adding that further research is needed to clarify what role IL-23 plays in those diseases. EARLY HEARING AID USE MAY HELP STAVE OFF DEMENTIA Hearing loss is a known risk factor for dementia, but early intervention might lower that risk, a new study suggests. Researchers performed hearing tests in nearly 3,000 volunteers without dementia who were at least 60 years old. Over the next 20 years, the researchers saw a 61% lower risk for eventual dementia among those with newly diagnosed hearing loss who started wearing hearing aids before age 70, compared to participants diagnosed with hearing impairment at a similar age who did not get hearing aids, they reported in JAMA Neurology. Hearing aid use did not appear to protect against dementia in people diagnosed with a hearing problem after age 70, however. "Only 17% of individuals with moderate to severe hearing loss use hearing aids," the researchers noted. "Our study underscores the importance of early intervention" to reduce the risk of dementia associated with hearing loss, they concluded.
